

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	SERIAL NO. Not Yet Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		FILING DATE Herewith	GROUP Not Yet Assigned

## U.S. PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	<del>Avandia Drug Profile. PDR Health Website - www.pdrhealth.com</del> no date
	Weinstock, et al. <i>Int'l. J. Exp. Clin. Pharmacol.</i> , <u>54</u> : 169-178 (1997).
	Iwamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled By Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , <u>13</u> : 365-370 (1995).
	Alberti, et al., "A Desktop Guide for the Management of Non-Insulin Dependent Diabetes Mellitus (NIDDM): An Update". <i>Diabetic Medicine</i> , <u>11</u> : 899-909 (1994).
	Iwamoto. "Usage of New Oral Anti-Diabetic Drugs". <i>Klinika</i> , <u>22(6)</u> pp. 445-450 (1995).
	Nakano, et al., "Clinical Evaluation of a New Oral Hypoglycemic Drug, CS-045, on Daily Profile of Blood Glucose in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Rinsyou Iyaku (Clinical Medicine)</i> , 9th Vol., Supp. 3: pp. 151-164 (1993).

EXAMINER	DATE CONSIDERED
	4/11/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
K	5,965,584	10/1999	Ikeda, et al.	514	342	
	US20020016287	2/7/02	Buckingham, et al.	514	3	
	US20020177612	11/28/02	Grannett, et al.	514	340	
	6,291,495	9/18/01	Rieveley	514	369	
	6,153,632	11/28/00	Rieveley	514	369	
	5,972,973	10/26/99	Whitcomb	514	342	
	5,859,037	1/12/99	Whitcomb	514	369	
	5,952,356	9/14/99	Ikeda, et al.	514	340	
	6,150,383	11/21/00	Ikeda, et al.	514	342	
	6,031,004	2/29/00	Timmins, et al.	514	635	
	4,985,862	1/23/90	Alessi, et al.	514	360	
	5,068,342	11/26/91	Zask, et al.	548	183	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
K	WO 98/36755	8/1998	PCT				
	0 861 666	9/1998	EPO				
	WO 93/03724	3/1993	PCT				
	0 749 751	12/1996	EPO				
	0 306 228	3/1989	EPO				
	WO 99/03478	1/28/99	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

K	Kelley, et al., "Troglitazone", <i>Current Opinion in Endocrinology and Diabetes</i> , <u>5</u> (2): 90-96 (1998) (XP002080820).
	Scheen, et al., "Oral Antidiabetic Agents, A Guide to Selection", <i>Disease Management</i> , <u>55</u> (2): 225-236 (XP002080821).
	Scheen et al., "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Achievements and Future Developments". <i>Drugs</i> , <u>54</u> (3): 355-368 (1997) (XP002080822).
	Iwatamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , <u>13</u> (4): 365-370 (1996) (XP002064289).
	Gareth Williams. "Management of Non-Insulin-Dependent Diabetes Mellitus", <i>The Lancet</i> , <u>343</u> : 95-100 (1994).
	Kuzuya, et al., "A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Diabetes Research &amp; Clinical Practice</i> , <u>11</u> : 147-154 (1991).
	Lehmann, et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor $\gamma$ (PPAR $\gamma$ )". <i>J. Biol. Chem.</i> , <u>270</u> (22): 12953-12956 (1995).

EXAMINER	DATE CONSIDERED 4/1/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
✓	5,900,435	5/4/99	Martin D. Meglasson	514	565	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
✓	WO 97/17975	5/22/97	PCT				
✓	WO 95/21608	8/1995	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	Donnelly, et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and new Pharmacological Approaches to Metabolism". <i>Br. J. Clin. Pharmacol.</i> , <b>37</b> : 311-320 (1994).
	Jackson, et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes". <i>Diabetes</i> , <b>36</b> : 632-640 (1987).
	Hofmann, et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers". <i>Diabetes Care</i> , <b>15</b> (8): 1075-1078 (1992).
	Foot, et al., "Improved Metabolic Control by Addition of Troglitazone to Glibenclamide Therapy in Non-Insulin Dependent Diabetics". <i>Diabetologia</i> , <b>38</b> (S1): A44 (1995).
	Whitcomb, et al., "Thiazolidinediones". <i>Exp. Opin. Invest. Drugs</i> , <b>4</b> (12): 1299-1309 (1995).
	Leif C. Groop, "Sulfonylureas in NIDDM". <i>Diabetes Care</i> , <b>15</b> (6): 737-754 (1992).
	Vialettes, et al., "Pharmacological Approach in the Treatment of Insulin Resistance". <i>Horm. Res.</i> , <b>38</b> : 51-56 (1992).
	Sohda, et al., "Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its Derivatives". <i>Chem. Pharm. Bull.</i> , <b>30</b> (10): 3580-3600 (1982).
✓	Harold E. Lebovitz, "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , <b>17</b> (12): 1542-1544 (1994).
✓	Iwamoto, et al., "effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM". <i>Diabetes Care</i> , <b>14</b> (11): 1083-1086 (1991).

EXAMINER

DATE CONSIDERED

4/1/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31828C3	PRED. SERIAL NO. 10/103,326
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE March 21, 2002	GROUP Not Yet Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hotta. <i>Tonyoby</i> , <u>Update 10</u> , pp. 68-77, April 1994 (with translation).
	Hotta. <i>Chronic Disease</i> , <u>6(1)</u> , January 5, 1995.
	Ishida, et al., "Oral Hypoglycemic Agents – New Oral Drugs and New Strategy of Treatment". <i>Clinic All-Round</i> , 43: 2615-2621 (1994).
	Cusi, et al., "Metformin: A Review of its Metabolic Effects". <i>Diabetes Review</i> , <u>6(2)</u> : 89-131 (1998).
	Arshag D. Mooradian. "Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly". <i>Drugs</i> , <u>51(6)</u> : 931-941 (1996).
	Windholz, et al., <i>The Merck Index</i> , <u>10th Edition</u> , pp. 635. Abstract Nos. 4300 & 4302 (1983).
	K. Doi, "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Development". <i>J. Japan Diabetes Science</i> , <u>3(Supp. 1)</u> : 962-973 (1990).
	Kramer, et al., "Differential Interaction of Glimepiride and Glibenclamide with the Beta-Cell Sulfonylurea Receptor 2 Photoaffinity-Labeling of a 65 KDA Protein by H-3 Glimepiride. <i>Biochim. et Biophys. Acta-Biomembranes</i> , <u>1191(2)</u> : 270-290 (1994).
EXAMINER	DATE CONSIDERED 4/1/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.